NCT03525990

Brief Summary

PRO-COM Project: Randomized-controlled study evaluating the impact of electronic patient reported outcome (ePRO) surveys on patient-physician communication and quality of life in patients with advanced breast cancer

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
62

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jan 2018

Longer than P75 for not_applicable

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 10, 2018

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

April 24, 2018

Completed
22 days until next milestone

First Posted

Study publicly available on registry

May 16, 2018

Completed
4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 30, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2022

Completed
Last Updated

April 21, 2023

Status Verified

April 1, 2023

Enrollment Period

4.3 years

First QC Date

April 24, 2018

Last Update Submit

April 19, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Patient-physician communication

    The communication between patient and physician will be assessed with EORTC QLQ-COMU26. Presumably some patients have privacy concerns with electronic questionnaires. The EORTC-COMU26 is the most important questionnaire in this study because it is needed for the primary endpoint. It contains sensitive questions about how the patient experiences the communication during the visit. In order to avoid patients not filling out the questionnaire due to privacy concerns or being afraid of giving an honest opinion and the physician could read it electronically, the EORTC QLQ-COMU26 is paper-based and the patients can hand them in in the study office.

    Up to six months

Secondary Outcomes (3)

  • Quality of life assessment

    Arm A: at every visit for six months; Arm B: at baseline, three months, six months

  • Frequency of discontinuations of therapy

    Up to six months

  • Duration of communication between physician and patient

    At baseline, three months, six months in both groups

Study Arms (2)

Intervention Arm

ACTIVE COMPARATOR

Quality of life questionnaires (electronic patient reported outcomes) to be filled out by the patients at every visit. Quality of life data is fully available for physicians. Paper-based questionnaire (EORTC QLQ-COMU26) at baseline, after three months and after six months.

Other: Questionnaires

Control Arm

PLACEBO COMPARATOR

Quality of life questionnaires (electronic patient reported outcomes) only to filled out by the patients at baseline, after three months and after six months. Quality of life data is hidden for physicians. Paper-based questionnaire (EORTC QLQ-COMU26) at baseline, after three months and after six months.

Other: Questionnaires

Interventions

Quality of life questionnaires on iPads with CHES (Computer-based Health Evaluation System), paper-based questionnaire (EORTC QLQ-COMU26)

Control ArmIntervention Arm

Eligibility Criteria

Sexfemale
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Stage IV breast cancer
  • Start of a systemic anti cancer therapy: chemotherapy -/+ antibody therapy 1st until 3rd line (palliative), endocrine therapy or other therapy without limit
  • Estimated life expectancy of minimum six months
  • Signed informed consent
  • No cognitive or speech impairments

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

A.ö. Krankenhaus St. Josef Braunau GmbH

Braunau am Inn, Upper Austria, 5280, Austria

Location

Klinikum Wels-Grieskirchen GmbH

Wels, Upper Austria, 4600, Austria

Location

MeSH Terms

Interventions

Surveys and Questionnaires

Intervention Hierarchy (Ancestors)

Data CollectionEpidemiologic MethodsInvestigative TechniquesHealth Care Evaluation MechanismsQuality of Health CareHealth Care Quality, Access, and EvaluationPublic HealthEnvironment and Public Health

Study Officials

  • Vera Trommet, Dr.

    Klinikum Wels-Grieskirchen GmbH, 4. Interne

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

April 24, 2018

First Posted

May 16, 2018

Study Start

January 10, 2018

Primary Completion

April 30, 2022

Study Completion

April 30, 2022

Last Updated

April 21, 2023

Record last verified: 2023-04

Data Sharing

IPD Sharing
Will not share

Locations